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RESEARCH ARTICLE
Transitions in auditory rehabilitation with bone conduction implants (BCI)
Maurizio Barbara, Edoardo Covelli, Chiara Filippi, Valerio Margani, Alessandra De Luca and Simonetta Monini
NESMOS Department, ENT Clinic, Sapienza University, Rome, Italy
ABSTRACT
Background: The bone conductive implants (BCI) are nowadays a reliable alternative for rehabilitation
of specific forms of hearing loss, i.e. conductive, mixed or single sided deafness (SSD).
Aims/Objective: To analyse the various factors in play when considering an auditory rehabilitation
with a bone-conductive device (BCI).
Materials and Methods: The clinical charts of subjects who underwent BCI application at the same
Implanting Center from 2005 to 2018 were retrieved analysing also the reason for eventual explant-
ation and the alternative option (transition) for hearing rehabilitation.
Results: Nine BAHA Compact, 4 BAHA Intenso, 21 BAHA Divino, 3 BAHA BP100, 4 Ponto, 2 Sophono, 5
Bonebridge, 5 BAHA5 Attract; 11 BAHA5 Connect were used in 12 unilateral COM; 16 bilateral COM; 3
unilateral cholesteatoma; 6 bilateral cholesteatoma; 2 unilateral otosclerosis; 5 bilateral otosclerosis; 9
congenital malformations; 6 major otoneurosurgical procedures; 5 sudden deafness. Explantation was
necessary for five subjects.
Conclusions: Middle ear pathology and sequels from surgery represent the most common reason for
BCI implantation, both in unilateral and in bilateral cases. Transition from one implantable device to
another one can be predictable, mostly when explantation is necessary.
Significance: The role of BCI for rehabilitation in middle ear pathology may be extremely important.
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Introduction
Middle ear surgery, in principle, aims for the simultaneous
resolution of both pathological and functional issues related
to the causative pathology. When a middle ear disease is
present, it initially causes a decline in the conductive mech-
anism of hearing, as shown by the presence of a mild-to-
moderate air-bone gap in pure tone audiometry. Although
this type of hearing loss is less disabling than purely sensori-
neural hearing loss, a conductive loss that affects both ears
can also compromise communication skills and quality of
life [1].
The most frequent permanent causes of conductive hear-
ing loss are related to chronic otitis media (COM) with or
without cholesteatoma, ear malformations and otosclerosis.
While surgery and its functional outcomes are quite stand-
ardised and reproducible for complicated COM, in cases of
ear malformations, functional recovery may require more
than a single surgical procedure, which can result in an
uncertain functional outcome. Therefore, in some of these
cases, subsequent auditory rehabilitation is required, primar-
ily using a conventional hearing aid (cHA), such as bone-
conduction glass-held HA.
Since their first introduction in the clinical field in the
late 1970s [2], bone conduction implants (BCI) have been
considered a possible alternative solution, initially for the
rehabilitation of conductive hearing loss. Thereafter, in light
of technological innovations in sound processors (SP), the
initial indications have been extended to mild/moderate
forms of mixed hearing loss, with bone conduction thresh-
old levels of 35 dB or better. In fact, in some forms of COM
and, mostly, otosclerosis, it is not unusual to observe a
decrease in the BC threshold over time, for which even the
use of a conventional bone- or air-conduction HA could
become inadequate.
The aim of the present retrospective study was to analyse
the experience with the use of different types of BCIs at a
single institution during the last fifteen years. In particular,
by retrieving data from a specific database, several factors
were taken into consideration, including the initial reasons
for selecting a BCI and the need for any eventual changes in
alternative solutions.
Material and methods
From 2005 to 2018, 64 subjects (29 males, 35 females; aged
15–86 years) from an entire patient population of 161 sub-
jects treated with a surgically implanted device at a tertiary
university referral implantation centre underwent BCI
implantation surgery for the rehabilitation of conductive,
mild-to-moderate mixed or single-sided (SSD) hearing loss.
The patients’ gender, age and type of device are listed in
Table 1.
The following brands of BCI were used: BAHA VR
(Cochlear, Melbourne, Australia), Ponto VR (OticonMedical,
Copenhagen, Denmark), Alpha 1 VR (Sophono, Medtronic,
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Minneapolis USA) and Bonebridge VR (Medel, Innsbruck,
Austria). According to the year of implantation, the subjects
received the most current and suitable system with the lat-
est-generation SP available from each company.
According to our protocol, all the subjects underwent a
thorough preoperative evaluation that included a simulation
trial session using a fitted, headband-worn SP tailored to
the individual’s functional needs [3]. Surgery was performed
according to the best-practice procedure recommended by
each company. In this regard, the greatest differences were
related to implantation with the BAHA VR device because
the incision underwent various technical evolutions ranging
from the initial rectangular, pedicled flap with total subcuta-
neous removal to a linear incision with subcutaneous
removal and the most recent procedure, a linear incision
without subcutaneous removal and the placement of a lon-
ger abutment.
Reasons for modifying the original choice, i.e. for transi-
tioning to a different option, were examined for both percu-
taneous and transcutaneous BCI systems.
Results
In total, 64 BCIs were implanted, always unilaterally, for
unilateral and bilateral hearing loss. The type and generation
of device SP depended on the year of implantation and the
availability of the device at the implantation centre. The SPs
were distributed as follows: 2004–2006 (9 BAHA VR
Compact; 4 BAHA VR Intenso); 2006–2010 (21 BAHA VR
Divino); 2010–2012 (3 BAHA VR BP100); 2013–2014 (4
Ponto VR ); 2013–2015 (2 Sophono VR ); 2012–2015 (5
Bonebridge VR ) (BB); 2015–2018 (5 BAHA5 VR Attract; 11
BAHA5 VR Connect). In total, 52 percutaneous and 12 trans-
cutaneous systems were implanted.
The underlying pathologies (Table 2) included 28 cases
of COM (12 unilateral, 16 bilateral), 9 cholesteatomas (3
unilateral, 6 bilateral), 7 cases of otosclerosis (2 unilateral, 5
bilateral), 9 congenital malformations (1 unilateral, 8 bilat-
eral), 6 unilateral skull base procedures and 5 cases of uni-
lateral idiopathic sudden deafness; in the latter 11 subjects,
the BCI was applied as an SSD protocol [4,5].
Among the postsurgical cases, 44 subjects had previously
undergone conventional middle ear surgery for the underly-
ing pathology: 28 for COM, 9 for COM with cholesteatoma
and 7 for otosclerosis. A single traditional middle ear pro-
cedure was performed in 17 COM subjects; the remaining
COM patients, including cholesteatoma cases, had under-
gone multiple surgeries: 10 subjects underwent 3 surgeries
or fewer and 10 subjects underwent 4 surgeries or more
(Table 3). The time lapse from the last middle ear surgery
was <1 year in 11 subjects; 1–5 years in 12 subjects;
>5 years in 10 subjects and >10 years in 11 subjects (Table
4). Twenty subjects, including the nine with ear malforma-
tions, had not undergone previous middle ear surgery. In
six cases, hearing loss was an unavoidable sequela of major
skull base procedures and led to an SSD condition. No sur-
gery was previously performed in the five cases of SSD
caused by idiopathic sudden deafness episodes.
Transitions from the original option to a different solu-
tion involved all types of devices (Table 5). Three subjects
with a percutaneous device required explantation: 1 case
because of skin dehiscence that prompted the implantation
of a transcutaneous device; 1 case because of skin over-
growth for which no other option was selected; and 1 case
due to a delayed loss of osteointegration and loss of the
fixture with no further options. In four subjects, the
decrease of the bone conduction threshold required an
upgrade to a more powerful SP. With transcutaneous devi-
ces, minor skin irritation/redness was resolved by tempor-
arily reducing the wearing time and switching to a weaker
magnet. In one case, the transcutaneous device was
removed due to painful symptomatology and replaced with
a percutaneous device.
Table 1. Demographic data of the study sample, including year of implant-
ation and type of bone conduction implant.
No
Gender
29 males, 35 females; 12–85 years
Year of implantation
2005–2018 64
Type of device
BAHA VR 53
SOPHONO VR 2
PONTO VR 4
BONEBRIDGE VR 5
Table 2. Pathologies underlying conductive or mixed hearing loss.
Pathology Unilateral Bilateral
COM 12 16
CCOM 3 6
Otosclerosis 2 5
Ear malformations 1 8
SSD 5
Post skull base procedures 6
COM: chronic otitis media; CCOM: chronic otitis media with cholesteatoma;
SSD: single-sided deafness.
Table 3. Time interval (in years) between the last middle ear surgery (MES)
and BCI implantation.
<1 year 1–5 years 5 years 10 years NO MES
11 12 10 12 19
Table 4. Number of previous conventional middle ear procedures (MES).
NO MES 1 2–3 >3
19 13 10 22
Table 5. Transitions involving BCI and the causative factors.
Original BCI Transition No Cause
pBCI tBCI 1 Skin dehiscence
1 OW-VSB tBCI 1 Hardware failure
BB pBCI 1 Retroauricular pain
pBCI – 1 Extrusion
pBCI – 1 Skin overgrowth
BAHA DIVINO BAHA5 1 Deterioration of bone conduction threshold
BAHA DIVINO BP100 2 Deterioration of bone conduction threshold
BAHA COMPACT INTENSO 1 Deterioration of bone conduction threshold
–: no transition.
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Discussion
The presence of middle ear pathology or sequelae from con-
ventional middle ear surgery for variable degrees of con-
ductive or mixed hearing loss most often represent a local
contraindication for wearing a cHA. Therefore, under these
circumstances, the use of an alternative solution may be
required. The timing of implantation and the selection of
the appropriate implantable device depend on different fac-
tors that are in primis linked to their actual availability at an
implantation centre. For example, all the possible solutions
that could be proposed for conductive or mixed hearing
loss, including a conventional HA, BCI or an active middle
ear implant (AMEI), should be taken into consideration.
For the two implantable solutions, the decision would
depend on the availability of the device but also on other
factors, including the specific surgical experience of the
centre itself and the reliability of the device in the long
term. In this latter regard, BCIs have been the only implant-
able solution available for many years. They have been
applied worldwide, generating many reports with long-term
follow-up outcomes that have confirmed their efficacy.
AMEIs were introduced in the mid-2000s; consequently,
they have had a shorter existence and have generated fewer
and shorter follow-up reports. In addition, their application
may require specific skills, so that only selected centres are
implanting them. Given these premises, it is reasonable to
assume that, especially in an otologic centre without prior
AMEI experience, BCIs would be the first logical choice.
The BCI group in the present study showed an uneven
distribution among the four types of devices, and percutan-
eous systems (pBCI) were more prevalent than transcutane-
ous systems (tBCI), namely, BAHA Attract VR [6], Sophono
VR [7] and BoneBridge VR [8]. This finding is primarily
related to the fact that tBCIs have only recently been made
available in clinical practice. The advent of the tBCI was
welcomed with the hope of overcoming some negative
issues related to pBCI, such as the need for daily care, the
unaesthetic screw exposure and the potential skin complica-
tions; however, at least for the passive tBCI (Sophono VR ,
BAHA Attract VR ), a slightly inferior functional performance
due to the interposed skin attenuation should be expected,
especially at the high-frequency level. Personal limited
experience with tBCI indicates that in only one case, the
adoption of such a system (Sophono VR ) was necessary to
address skin problems that occurred after a previously posi-
tioned pBCI (BAHA VR ), while the other tBCI was selected
and applied as the first choice, mostly for aesthetic reasons.
Since the start of the BCI programme at our implantation
centre, many patients were considered candidates for this
type of rehabilitation, including those with unilateral and
bilateral cases of cholesteatomatous (CCOM) and noncho-
lesteatomatous COM, otosclerosis, ear malformations and
SSD. Following an economics-related policy of device sup-
ply, only one ear was implanted, even in the presence of a
bilateral functional need. Despite this fact, the BCI-
implanted population has been shown to achieve a high
level of satisfaction with other types of implantable solutions
[9]. The factor that determined ear selection was the side
with a higher bone conduction threshold, from which a bet-
ter functional performance could be expected. Among the
subjects who had undergone previous operations, the num-
ber of previous procedures did not seem to influence the
patient’s choice. Multiple surgeries were generally related to
CCOM and were less likely in cases of otosclerosis or ear
malformations. In cases of otosclerosis specifically, none of
the subjects had undergone any prior middle ear surgical
attempt (canalplasty with ossicular reconstruction), and they
preferred a BCI for their auditory rehabilitation. A unilateral
BCI was obviously adopted in the SSD cases. In some tBCI
subjects, some issues with the magnetic contact were
noticed, especially during the initial period after implant
activation [10]; in some others, skin redness over the
internal magnet site was observed and required a reduction
of the daily wearing time; finally, one subject (fitted with a
BoneBridge VR with retrosigmoid placement) asked to be
explanted due to retroauricular pain that resolved after sur-
gical removal of the BCI, which prompted a request for
a pBCI.
Because our findings were not derived from a rando-
mised trial, it is not possible to draw any conclusions
regarding the hypothesis that BCI could be the best rehabili-
tative option to offer and/or whether affected subjects would
prefer it to, for instance, classical middle ear surgical revi-
sion. To answer this question, one would need to perform a
retrospective analysis of all cases in which classical middle
ear surgery was performed before and after the availability
of BCI and with a similar observational time. What seems
to be important, however, is that, as routinely occurs at our
implantation centre, all potential BCI candidates receive
thorough information on the existence of a rehabilitative
option that, with respect to the classical middle ear proce-
dures, also offers the non-insignificant advantage of prevent-
ing any further hearing deterioration, as may sometimes
occur during revision middle ear surgery. It is also our con-
viction that the routine adoption of a preoperative headband
test with a fitted SP could encourage the patient to accept
this implantable auditory solution.
Despite an overall successful BCI experience, a few sub-
jects experienced some issues that required a change from
the original plan; in some cases, this change included
explantation and/or another solution, such as returning to
cHA, adopting a more powerful BCI system, or placing an
active middle ear implant (AMEI). The transition process,
therefore, encompasses not only the first option motivated
by the underlying pathology but also the postimplanta-
tion period.
It is possible to conclude that transition is a phenomenon
that affects several aspects of BCI implantation, from selec-
tion in accordance with the underlying pathology to the
possible need for solutions other than the original option.
This possibility should always be thoroughly discussed with
the potential candidate during preoperative counselling.
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